Budoprutug - Eliem Therapeutics
Alternative Names: TNT-119Latest Information Update: 03 Jul 2024
At a glance
- Originator Tenet Medicines
- Developer Eliem Therapeutics
- Class Anti-inflammatories; Monoclonal antibodies
- Mechanism of Action CD19 antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Idiopathic thrombocytopenic purpura; Membranous glomerulonephritis; Systemic lupus erythematosus
Most Recent Events
- 27 Jun 2024 Tenet Medicines has been acquired and merged into Eliem Therapeutics
- 11 Apr 2024 Eliem Therapeutics and Tenet Medicines plans a phase II trial for Idiopathic thrombocytopenic purpura and Systemic lupus erythematosus in the second half of 2024
- 11 Apr 2024 Phase-I clinical trials in Idiopathic thrombocytopenic purpura (IV) prior to April 2024